All In Biotech

Drug Trial Radar · NCT02255656

Phase IIIB-IV Long-Term Follow-up Study for Patients Who Participated in CAMMS03409

A Long-term Follow-up Study for Multiple Sclerosis Patients Who Have Completed the Alemtuzumab Extension Study (CAMMS03409)

Last checked: Nov 20, 2026Latest source record: Mar 28, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

1,062

Actual

Start

Jan 7, 2015

Primary completion

Jul 15, 2020

Study completion Jul 15, 2020

Sponsor

Lead sponsor
Genzyme, a Sanofi CompanySanofi (SNY)
Sponsor type
Industry
First posted
Oct 2, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Primary Objective: To evaluate long-term safety of alemtuzumab. Secondary Objectives: * To evaluate long term efficacy of alemtuzumab. * To evaluate the safety profile of participants who received other Disease Modifying Treatment (DMT) following alemtuzumab treatment. * To evaluate participant-reported Quality of Life (QoL) outcomes and health resource utilization of participant who received alemtuzumab. * To evaluate as needed re-treatment with alemtuzumab and other DMTs.

Conditions

  • Relapsing Remitting Multiple Sclerosis

Interventions

  • alemtuzumab GZ402673Drug

    Pharmaceutical form:concentrate for solution for infusion Route of administration: intravenous

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Treatment-Emergent Adverse Events (TEAEs), and Treatment-Emergent Serious Adverse Events (TESAEs)Time frame: From Baseline until the end of the study (up to a maximum duration of 5.6 years)
  2. Number of Participants With Infusion-Associated Reactions (IAR)Time frame: Within 24 hours of any alemtuzumab infusion
  3. Number of Participants With Adverse Events of Special Interest (AESI)Time frame: From Baseline until the end of the study (up to a maximum duration of 5.6 years)
  4. Number of Participants With Potentially Clinically Significant Laboratory AbnormalitiesTime frame: From Baseline until the end of the study (up to a maximum duration of 5.6 years)

Locations

131 sites in 19 countries. Site status is shown where the registry gives one.

  • Investigational Site Number 1086

    Cullman, Alabama

  • Investigational Site Number 1031

    Phoenix, Arizona

  • Investigational Site Number 1171

    Phoenix, Arizona

  • Investigational Site Number 1090

    Tucson, Arizona

  • Investigational Site Number 1040

    Berkeley, California

  • Investigational Site Number 1152

    Fullerton, California

  • Investigational Site Number 1093

    Pasadena, California

  • Investigational Site Number 1027

    Fort Collins, Colorado

  • Investigational Site Number 1078

    Jacksonville, Florida

  • Investigational Site Number 1059

    Maitland, Florida

  • Investigational Site Number 1173

    Sarasota, Florida

  • Investigational Site Number 1034

    Sunrise, Florida

  • Investigational Site Number 1005

    Tampa, Florida

  • Investigational Site Number 1049

    Tampa, Florida

  • Investigational Site Number 1008

    Northbrook, Illinois

  • Investigational Site Number 1001

    Fort Wayne, Indiana

  • Investigational Site Number 1024

    Indianapolis, Indiana

  • Investigational Site Number 1017

    Des Moines, Iowa

  • Investigational Site Number 1022

    Kansas City, Kansas

  • Investigational Site Number 1083

    Lenexa, Kansas

  • Investigational Site Number 1039

    Lexington, Kentucky

  • Investigational Site Number 1021

    Louisville, Kentucky

  • Investigational Site Number 1061

    Wellesley, Massachusetts

  • Investigational Site Number 1028

    Worcester, Massachusetts

  • Investigational Site Number 1025

    Ann Arbor, Michigan

  • Investigational Site Number 1020

    Detroit, Michigan

  • Investigational Site Number 1054

    Traverse City, Michigan

  • Investigational Site Number 1084

    Kansas City, Missouri

  • Investigational Site Number 1092

    St Louis, Missouri

  • Investigational Site Number 1073

    Teaneck, New Jersey

  • Investigational Site Number 1014

    Albuquerque, New Mexico

  • Investigational Site Number 1081

    Mineola, New York

  • Investigational Site Number 1026

    New York, New York

  • Investigational Site Number 1160

    Patchogue, New York

  • Investigational Site Number 1015

    Rochester, New York

  • Investigational Site Number 1053

    Syracuse, New York

  • Investigational Site Number 1095

    Chapel Hill, North Carolina

  • Investigational Site Number 1082

    Winston-Salem, North Carolina

  • Investigational Site Number 1035

    Cleveland, Ohio

  • Investigational Site Number 1058

    Uniontown, Ohio

Showing 40 of 131 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.